Free lessons on FDA decisions, clinical trials, cash runway and who owns the stock. Each one uses a real past example you can check yourself on BiopharmaWatch.
New to biotech stocks? Read these in order. About an hour in total, and every lesson stands on its own too.
Why biotech moves differently, and the 5 things to check before you buy.
Phase 1, 2 and 3 in plain words, and why Phase 3 results move stocks most.
The FDA's decision deadline, how it is set, and what happens before and after.
When the FDA says not yet. What it means for the stock, and what can come next.
How long the money lasts, and why short runways often mean new shares.
Who owns the stock, and which insider buys have mattered in the past.
How to read a crowded short, and when it has not helped.
Put it all together, tested on 22,234 past stock-months.
Short, direct answers to the questions biotech investors search for most. New lessons are added every week.
Every lesson uses real history from our own data. Nothing here is a tip.
Corcept fell from $70.20 to $34.80 in one day on an FDA rejection (Dec 2025), then closed at $123.57 in Aug 2026 after a different approval.
14-box checklist · RYTM+621%Rhythm had 10 of 14 boxes green in June 2022. Six months later the stock was up 621%.
Approval day · 1,191 approvals47%In our records, the stock was lower after the news on 47% of FDA approvals. The run-up usually happens before the date.
Every lesson links to the tool that shows it: the FDA calendar, the screener, hedge funds and insiders.
Prefer one long page? The Biotech Investing 101 full guide covers the same ground in 17 short lessons.
Educational content only. Not financial advice. Past results don't predict future ones.